AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05048836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 6 months
Description: Food subsidy for 6 months
Study NCT05048836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 12 months
Description: Food subsidy for 12 months
Study NCT05048836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 6 months
Description: lifestyle support intervention delivered by community health workers for 6 months
Study NCT05048836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 12 months
Description: lifestyle support intervention delivered by community health workers for 6 months
Study NCT05048836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 6 months
Description: Twice monthly delivery of healthy food for 6 months
Study NCT05048836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 12 months
Description: Twice monthly delivery of healthy food for 12 months
Study NCT05077475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1H Tab. and C52R2 Tab.
Description: Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Study NCT05077475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52L
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
Study NCT06102590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized red blood cell transfusion strategy
Description: Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
Study NCT06769373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whirlpool Bath
Description: This group of participants will receive an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, whirlpool bath (32-38 °C) 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
Study NCT06769373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Bath
Description: This group of participants will recieve an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, contrast bath therapy which consist of 4 minutes hot water (38°C) followed by 1 minute cold water (10°C) periods for 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
Study NCT05841420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
Study NCT05841420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
Study NCT05841420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
Study NCT06769451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy
Description: STAR with a single dose of 25Gy(RBE) Proton Therapy
Study NCT06762366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional Incentive
Description: During this behavioral intervention, participants will be given additional compensation for correct answers.
Study NCT06762366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Response Delay
Description: During this behavioral intervention, participants will not be allowed to respond with their judgements until after a certain amount of time has passed.
Study NCT06762366 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Performance
Description: In this intervention, the participant completes the task as it is typically administer for a baseline performance measure. The participant can respond at will and does not receive incentive for correct responses.
Study NCT06755294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular incision subperiostal tunnel technique
Description: The VISTA (Vestibular Incision Subperiosteal Tunnel Access) technique is a minimally invasive surgical approach for root coverage. A single vertical incision is made, often at the labial frenulum for optimal access, reaching the periosteum to elevate a subperiosteal tunnel. This tunnel is extended beyond the mucogingival junction and interproximally under each papilla to enable tension-free coronal repositioning of the gingiva.~An autologous connective tissue graft, harvested and de-epithelialized from the palate, is introduced into the tunnel. Before placement, teeth are etched (orthophosphoric or hydrofluoric acid depending on surface type). Sutures (6-0 polypropylene) stabilize the graft, with additional composite fixation on treated teeth. The vertical incision is closed using 5-0 sutures, ensuring proper stabilization and healing. This approach minimizes trauma, promotes healing, and achieves effective root coverage.
Study NCT06755294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: The Coronally Advanced Flap (CAF) is an effective technique for root coverage in single or multiple gingival recession cases with adequate apical keratinized tissue thickness and height. Following the De Sanctis and Zucchelli protocol (2007), two horizontal incisions are made 3 mm apart, with placement 1 mm apical to the recession height. Vertical beveled incisions extend into the alveolar mucosa, and a flap is elevated in three stages: partial thickness at the papilla, full thickness to the buccal bone table, and apical partial thickness to release muscle fibers for mobility.~An autologous connective tissue graft (≥1 mm thick) is harvested from the palatal or retromolar area, de-epithelialized, and shaped to the recession size. The anatomical papillae are de-epithelialized, and the graft is sutured apically to the CEJ using 6-0 Polyglactin 910. Sling sutures (6-0 polypropylene) stabilize the flap 2 mm coronally to the CEJ, ensuring optimal positioning and healing.
Study NCT05986318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl cysteine
Description: NAC capsules
Study NCT05986318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Dexamethasone tablets
Study NCT05986318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl cysteine Placebo
Description: Matching placebo for NAC capsules
Study NCT05986318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl cysteine Placebo
Description: Matching placebo for NAC capsules
Study NCT05986318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Placebo
Description: Matching placebo for dexamethasone tablets
Study NCT05986318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Placebo
Description: Matching placebo for dexamethasone tablets
Study NCT06102590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European guidelines red blood cell transfusion strategy
Description: RBCT according to ESICM guidelines
Study NCT05512065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the right and left uterine arteries and umbilical artery.
Study NCT05986318 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
Study NCT05986318 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
Study NCT06772493 — intervention group
Intervention type: DEVICE
Intervention: ViewFlex X ICE System
Description: Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System
Study NCT06776432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivopixant
Description: Administered as specified in the treatment arm
Study NCT06776432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT06776432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administered as specified in the treatment arm
Study NCT06776432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SASS-001
Description: Administered as specified in the treatment arm
Study NCT06776549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature control
Description: Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
Study NCT06776549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature control
Description: Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: recommended dose, po
Study NCT05820152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFS-02 Injection
Description: The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
Study NCT04122183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iManage (my hearing loss)
Description: An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
Study NCT05422365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG), 10% solution for infusion
Description: The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample colleciton
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, SPECT/CT
Study NCT06145633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT06145633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT06145633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given 177Lu-PSMA-617
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68Ga-PSMA-11 PET
Study NCT06145633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT06145633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given IV
Study NCT05108272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
Study NCT05108272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Collagen Induction
Description: It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
Study NCT05865340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health + MED diet
Description: oral health + MED diet education
Study NCT05865340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health
Description: oral health education
Study NCT05865340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MED diet
Description: MED diet education
Study NCT05742165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
Study NCT05325294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed 780G System
Description: MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
Study NCT05496491 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiotherapy
Description: 5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
Study NCT05496491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: 5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
Study NCT05496491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: 8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
Study NCT05496491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Chemotherapy
Description: CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
Study NCT06197269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration antibiotics
Description: antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
Study NCT06197269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard duration antibiotics
Description: Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
Study NCT06247371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m\^2, Q2W, day1, i.v.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m\^2, Q3W, day1, i.v.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5, Q3W, day1, i.v.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, Q3W, day1, i.v.
Study NCT05504278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platinum
Description: 75mg/m\^2, Q3W, day1, i.v.
Study NCT05658848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative infertility counseling
Description: Collaborative infertility counseling for coping stratigies and marital satisfaction
Study NCT06777368 — intervention group
Intervention type: DEVICE
Intervention: Medtronic TAV
Description: Medtronic TAV where commercially available
Study NCT06777368 — intervention group
Intervention type: DEVICE
Intervention: Edwards TAV
Description: Edwards TAV where commercially available.
Study NCT06767787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.
Study NCT06767787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
Study NCT00995397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% lotion
Description: Small amount applied over the lesion twice a day for 7 days.
Study NCT06765096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Virtual Reality Model
Description: Participants will receive one session on educational virtual reality (VR) model for pelvic floor anatomy.
Study NCT06771791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral provocation test
Description: Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
Study NCT06771791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral provocation test
Description: Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
Study NCT06580275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS
Description: All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
Study NCT06759844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Booklet
Description: A printed booklet containing general information on chronic disease management provided to participants for reference without interactive or digital features